Meeting
2024 ASCO Gastrointestinal Cancers Symposium
Clinical impact of KRAS mutations in metastatic pancreatic ductal adenocarcinoma (PDAC).
Authors
Carter Norton
Huntsman Cancer Institute, University of Utah Health, Salt Lake City, UT
Carter Norton , Jarrod Smith , Zach Rubnitz , Grace H. Tan , Christopher Duane Nevala-Plagemann , Heloisa P. Soares , Ignacio Garrido-Laguna , Vaia Florou
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer
Sub Track
Patient-Reported Outcomes and Real-World Evidence
Citation
J Clin Oncol 42, 2024 (suppl 3; abstr 619)
DOI
10.1200/JCO.2024.42.3_suppl.619
Abstract #
619
Poster Bd #
J6
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Prognostic indicators of KRAS G12X mutations in pancreatic cancer.
First Author: Bach Ardalan
Poster
2022 ASCO Annual Meeting
KRAS wild-type pancreatic ductal adenocarcinoma: Molecular and therapeutic opportunities.
First Author: Aakash Desai
Poster
2021 Gastrointestinal Cancers Symposium
Real-world study of treatment patterns and outcomes among patients with metastatic pancreatic ductal adenocarcinoma (PDAC) in Europe.
First Author: Julien Taieb
Poster
2020 ASCO Virtual Scientific Program
Comprehensive analysis of KRAS variants in patients (pts) with pancreatic cancer (PDAC): Clinical/molecular correlations and real-world outcomes across standard therapies.
First Author: Andrew Eugene Hendifar